View source for Rosai-Dorfman-Destombes disease

<span id="BackToTop"></span>
<div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px">
[[#top|Back to Top]]
</div>
{{#lst:Editorial board transclusions|hist}}
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}
=Guidelines=
'''Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.'''
==Consensus guidelines==
*'''2018:''' Abla et al. [http://www.bloodjournal.org/content/131/26/2877.long Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease] [https://pubmed.ncbi.nlm.nih.gov/29720485/ PubMed]
==[https://www.nccn.org NCCN]==
*''NCCN does not currently have guidelines at this granular level; please see [https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1502 NCCN Guidelines - Histiocytic Neoplasms].''

=All lines of therapy=
==Cobimetinib monotherapy {{#subobject:a6f6dd|Regimen=1}}==
<div class="toccolours" style="background-color:#eeeeee">
===Regimen {{#subobject:#fecb7f|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable sortable" style="width: 60%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|Dates of enrollment
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438729/ Diamond et al. 2019 (MSK 15-216)]
|2016-NR
|style="background-color:#ffffbe"|Phase 2, fewer than 20 pts in this arm (RT)
|-
|}
''Note: there were N=2 patients with this type of histiocytosis.''
<div class="toccolours" style="background-color:#b3e2cd">
====Targeted therapy====
*[[Cobimetinib (Cotellic)]] 60 mg PO once per day on days 1 to 21
'''28-day cycles'''
</div></div>
===References===
# '''MSK 15-216:''' Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Mar;567(7749):521-524. Epub 2019 Mar 13. [https://doi.org/10.1038/s41586-019-1012-y link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438729/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30867592/ PubMed] [https://clinicaltrials.gov/study/NCT02649972 NCT02649972]
[[Category:Rosai-Dorfman-Destombes disease regimens]]
[[Category:Disease-specific pages]]
[[Category:Histiocytoses]]